Research analysts at StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Get Free Report) in a report issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Trading Down 15.7 %
Shares of NASDAQ:PIRS opened at $13.60 on Thursday. Pieris Pharmaceuticals has a 1 year low of $6.20 and a 1 year high of $22.32. The business has a fifty day simple moving average of $15.72 and a 200 day simple moving average of $14.82. The firm has a market cap of $17.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.61.
Hedge Funds Weigh In On Pieris Pharmaceuticals
A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. bought a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned approximately 1.21% of Pieris Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 40.11% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Read More
- Five stocks we like better than Pieris Pharmaceuticals
- Pros And Cons Of Monthly Dividend Stocks
- Work and Play: Investing in the Rise of Bleisure Travel
- How to Calculate Options Profits
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- High Flyers: 3 Natural Gas Stocks for March 2022
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
